Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Retirements at Urologic and AngioDynamics, and a new CFO at Zeltiq Aesthetics.

You may also be interested in...



News In Brief

Medtronic opens Shanghai innovation center. Justice Department ICD investigation nears resolution. BD buys dye maker Sirigen. More news briefs.

People In Brief

Device lobby hire: Elizabeth Pika moves from her post as legislative director for Rep. Tammy Baldwin, D-Wis., to become VP-government affairs at AdvaMed. Pika, replacing Seth Radus who left in May to join AdvaMed member firm Siemens, will play a particularly active role in advocating for the reform of how Medicare reimburses for molecular diagnostics in the model of the pending "Medicare Advanced Laboratory Diagnostics Act" (1"The Gray Sheet" Dec. 10, 2007, p. 13). Pika will report to Brett Loper, who joined AdvaMed in May to work with David Nexon in running the association's lobbying efforts (2"The Gray Sheet" May 5, 2008, p. 6)

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel